MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$5,201K
Proceeds from the
exercise of stock options
$1K
(-50.00%↓ Y/Y)
Net cash provided by
financing activities
$5,202K
(-50.40%↓ Y/Y)
Effect of foreign
currency on cash
$8K
Net increase in cash
and cash...
-$1,502K
(-163.40%↓ Y/Y)
Canceled cashflow
$5,210K
Stock-based compensation
$1,051K
(-43.07%↓ Y/Y)
Non-cash interest
expense
$126K
Amortization of debt issuance
costs
$77K
Non-cash lease expense
$51K
(-56.03%↓ Y/Y)
Depreciation and
amortization
$18K
(-45.45%↓ Y/Y)
Net cash used in
operating activities
-$6,684K
(17.20%↑ Y/Y)
Canceled cashflow
$1,323K
Net cash used in
investing activities
-$28K
(39.13%↑ Y/Y)
Net loss
-$6,356K
(43.67%↑ Y/Y)
Accounts payable
-$967K
(-200.42%↓ Y/Y)
Change in fair value of
liability classified...
-$397K
Prepaid expenses and
other current assets
$164K
(428.00%↑ Y/Y)
Operating lease
liabilities
-$51K
(51.43%↑ Y/Y)
Accrued expenses
-$49K
(57.39%↑ Y/Y)
Increase (decrease) in
other current...
-$23K
(-106.25%↓ Y/Y)
Purchase of equipment
$28K
(-39.13%↓ Y/Y)
Back
Back
Cash Flow
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)
source: myfinsight.com